Effect of Double Substitution in Cationic Chitosan Derivatives on DNA Transfection Efficiency

被引:11
作者
Badazhkova, Veronika D. [1 ]
Raik, Sergei, V [1 ,2 ]
Polyakov, Dmitry S. [3 ]
Poshina, Daria N. [1 ]
Skorik, Yury A. [1 ]
机构
[1] Russian Acad Sci, Inst Macromol Cpds, Bolshoi Pr VO 31, St Petersburg 199004, Russia
[2] Univ Helsinki, Fac Pharm, Div Pharmaceut Biosci, POB 56, FI-00014 Helsinki, Finland
[3] Inst Expt Med, Akad Pavlova St 12, St Petersburg 197376, Russia
基金
俄罗斯科学基金会;
关键词
chitosan; polyplex; cell transfection; gene delivery; GENE-THERAPY; PROTON-SPONGE; IN-VITRO; DELIVERY; POLYPLEXES; VECTORS; DESTABILIZATION; NANOPARTICLES; MECHANISM;
D O I
10.3390/polym12051057
中图分类号
O63 [高分子化学(高聚物)];
学科分类号
070305 ; 080501 ; 081704 ;
摘要
Recently, much effort has been expended on the development of non-viral gene delivery systems based on polyplexes of nucleic acids with various cationic polymers. Natural polysaccharide derivatives are promising carriers due to their low toxicity. In this work, chitosan was chemically modified by a reaction with 4-formyl-n,n,n-trimethylanilinium iodide and pyridoxal hydrochloride and subsequent reduction of the imine bond with NaBH4. This reaction yielded three novel derivatives, n-[4-(n',n',n'-trimethylammonium)benzyl]chitosan chloride (TMAB-CS), n-[(3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridine)methyl]chitosan chloride (Pyr-CS), and n-[4-(n',n',n''-trimethylammonium)benzyl]-n-[(3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridine)methyl]chitosan chloride (PyrTMAB-CS). Their structures and degrees of substitution were established by H-1 NMR spectroscopy as DS1 = 0.22 for TMAB-CS, DS2 = 0.28 for Pyr-CS, and DS1 = 0.21, DS2 = 0.22 for PyrTMAB-CS. Dynamic light scattering measurements revealed that the new polymers formed stable polyplexes with plasmid DNA encoding the green fluorescent protein (pEGFP-N3) and that the particles had the smallest size (110-165 nm) when the polymer:DNA mass ratio was higher than 5:1. Transfection experiments carried out in the HEK293 cell line using the polymer:DNA polyplexes demonstrated that Pyr-CS was a rather poor transfection agent at polymer:DNA mass ratios less than 10:1, but it was still more effective than the TMAB-CS and PyrTMAB-CS derivatives that contained a quaternary ammonium group. By contrast, TMAB-CS and PyrTMAB-CS were substantially more effective than Pyr-CS at higher polymer:DNA mass ratios and showed a maximum efficiency at 200:1 (50%-70% transfected cells). Overall, the results show the possibility of combining substituent effects in a single carrier, thereby increasing its efficacy.
引用
收藏
页数:15
相关论文
共 44 条
  • [1] Behr JP, 1997, CHIMIA, V51, P34
  • [2] Recent Advances in Chitosan-Based Carriers for Gene Delivery
    Cao, Ye
    Tan, Yang Fei
    Wong, Yee Shan
    Liew, Melvin Wen Jie
    Venkatraman, Subbu
    [J]. MARINE DRUGS, 2019, 17 (06)
  • [3] Chitosan: An Update on Potential Biomedical and Pharmaceutical Applications
    Cheung, Randy Chi Fai
    Ng, Tzi Bun
    Wong, Jack Ho
    Chan, Wai Yee
    [J]. MARINE DRUGS, 2015, 13 (08) : 5156 - 5186
  • [4] Progresses towards safe and efficient gene therapy vectors
    Chira, Sergiu
    Jackson, Carlo S.
    Oprea, Iulian
    Ozturk, Ferhat
    Pepper, Michael S.
    Diaconu, Iulia
    Braicu, Cornelia
    Raduly, Lajos-Zsolt
    Calin, George A.
    Berindan-Neagoe, Ioana
    [J]. ONCOTARGET, 2015, 6 (31) : 30675 - 30703
  • [5] Glycosaminoglycan destabilization of DNA-chitosan polyplexes for gene delivery depends on chitosan chain length and GAG properties
    Danielsen, S
    Strand, S
    Davies, CD
    Stokke, BT
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2005, 1721 (1-3): : 44 - 54
  • [6] Structural analysis of chitosan mediated DNA condensation by AFM:: Influence of chitosan molecular parameters
    Danielsen, S
    Vårum, KM
    Stokke, BT
    [J]. BIOMACROMOLECULES, 2004, 5 (03) : 928 - 936
  • [7] Gardlík R, 2005, MED SCI MONITOR, V11, pRA110
  • [8] Ghosh Arkasubhra, 2007, Biotechnol Genet Eng Rev, V24, P165
  • [9] A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
    Hacein-Bey-Abina, S
    von Kalle, C
    Schmidt, M
    Le Deist, F
    Wulffraat, N
    McIntyre, E
    Radford, I
    Villeval, JL
    Fraser, CC
    Cavazzana-Calvo, M
    Fischer, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (03) : 255 - 256
  • [10] Inamdar N, 2010, POLYM SCI TECHNOL SE, P333